Among the 77 patients in Group B with prior heart failure treatment, the baseline medication usage prior to admission was as follows: 75.32% (58/77) were receiving ACE inhibitors, angiotensin receptor blockers, or angiotensin receptor–neprilysin inhibitors (ACEI/ARBs/ARNI); 84.41% (65/77) were on beta-blocker therapy; 51.94% (40/77) were treated with mineralocorticoid receptor antagonists (MRA); and only 18.18% (14/77) had been prescribed SGLT2 inhibitors. The gene discussed is NR3C2; the disease is heart failure.